Navigation Links
Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Date:5/20/2008

Statistically Significant Reduction of IBS Pain and Normalizing Motility

Effect Observed

SAN DIEGO, May 20 /PRNewswire/ -- Tioga Pharmaceuticals, Inc. today announced the results of a recent Phase 2b study of its oral kappa opioid receptor agonist, asimadoline, which demonstrated statistically significant results in the treatment of Irritable Bowel Syndrome (IBS). Asimadoline produced significant improvement in diarrhea-predominant (D-IBS) and alternating (A-IBS) patients across multiple parameters including the primary endpoint of pain, as well as secondary endpoints of urgency, frequency and bloating in both males and females. In D-IBS patients, therapeutic benefit was observed within the first month of treatment and was sustained for the three month duration of the trial. Asimadoline appeared to be well tolerated with no adverse events occurring in a dose-dependent manner throughout the randomized, double-blind, placebo-controlled, dose-ranging clinical trial involving 596 subjects. These data were featured today in a late-breaking oral presentation session at the Digestive Disease Week 2008 Annual Meeting.

Study Results

Of the 596 patients randomized in the trial, approximately 33 percent were characterized as D-IBS, 37 percent constipation predominant (C-IBS) and 31 percent alternating between diarrhea and constipation (A-IBS).

-- In the overall patient group, patients with at least moderate pain

achieved a 17 percent improvement in percent number of months with

adequate relief of IBS pain compared to placebo (40 percent vs. 23

percent) with both the 0.5 mg (p=0.006) and the 1.0 mg (p=0.005) dose

of asimadoline.

- Evaluation by IBS subtype revealed benefit in D-IBS and A-IBS

patients.

- Benefit in C-IBS patients was not observed.

- The rate of adverse events was similar in asimadoline and placebo

<
'/>"/>
SOURCE Tioga Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. ... that specializes in the development and sale of patented ... and active pharmaceutical ingredients (API) today announced the business ... API operation. 1. Following the September 2014 ...
(Date:1/22/2015)... SAN DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: ... 31, 2014. Revenue for the quarter was $423.0 million, a ... 2013 (a 14 percent increase on a constant currency basis). ... compared to the quarter ended December 31, 2013. Diluted earnings ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... Nov. 8, 2011 FDA approved Makena (hydroxyprogesterone caproate) ... of certain preterm births in women who have had ... before Makena was approved, a version of the active ... physicians requested the drug from a pharmacist who compounded ...
... MedBox (Pink Sheets: MDBX ) ( www.thedispensingsolution.com ... symbol to MDBX.  The company previously announced that their ... The company is a leader in the design, ... medicines. The free-standing unit features 60 or more slots ...
Cached Medicine Technology:FDA Statement on Makena 2MedBox Announces Ticker Symbol Change 2
(Date:1/22/2015)... has released a new blog post presenting the basic features ... Purchasing an accidental death and dismemberment rider for a car ... provides benefits if the insured dies in an accident. Accidental ... life insurance. , AD&D is not expensive and can ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... Initiatives taken by European governments and healthcare ... aimed at improving efficiency levels and reducing ... automation is proving to be a major ... pressure from governments across Europe to install ...
... Inc. (Nasdaq: NXXI ), a developer and marketer ... improve cardiovascular health, enhance memory and address chronic joint pain, ... the market - on Tuesday, May 12, 2009 for the ... The Company has scheduled a conference call to review the ...
... Million -- Same-Store Sales Increased 1.1% -- Net Cash Provided ... Improved 18.0% to $17.2 Million - , NEW YORK, May ... for the first quarter ended March 28, 2009. Key Highlights ... Adjusted FIFO EBITDA increased 7.8% to $19.7 million ...
... Hills High School ... Nationwide BETHESDA, Md., May 5 The Cystic Fibrosis Foundation ... will visit Vestavia Hills High School in Birmingham, Ala., to honor ... a life-threatening genetic disease. Students raised more than $17,000 for the ...
... opportunity.” Benjamin Franklin’s significant words uttered more than 250 years ago ... , ... New York, NY (Vocus) May 5, 2009 ... more than 250 years ago ring true for the Gift ...
... CORONA DEL MAR, Calif., May 5 ,Mayday, ... French phrase m,aider ("help me"), was appropriately celebrated ... (ASA) closed public website access to their Newsletter,s ... expert, Dr. Barry Friedberg, be able to document ...
Cached Medicine News:Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 3Health News:Nutrition 21 to Report Third Quarter Fiscal Year 2009 Financial Results on Tuesday, May 12, 2009 2Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 2Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 3Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 4Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 5Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 6Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 7Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 8Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 9Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 10Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 11Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 12Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 13Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 14Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 15Health News:CW's 7th Heaven Actress Mackenzie Rosman to Visit Birmingham Area High School to Honor Cystic Fibrosis Foundation Fundraising 2Health News:Bone Marrow Registry to Launch Groundbreaking Fundraising Technology to Overcome Madoff Crisis 2Health News:ASA 'May Day' - Stung By Exposure of Watergate-like Public Record Deletions, American Society of Anesthesiologists Closes Access to Website Newsletter 2
... Designed to accommodate a variety of applications ... the AMAX DestinyPlus is suitable for any ... environment. With a mixed-mode throughput exceeding 95 ... perform a full range of chromogenics, the ...
The TCM4 is able to detect patient changes and is portable....
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
... is the only online source of nationally ... critical care nurses and other healthcare professionals., ... so you can take them at your ... certificate is issued upon course completion. The ...
Medicine Products: